Health policy and regulatory authorities: challenges of technology regulation in Public Health Emergencies

被引:0
作者
Oliveira, Catia Veronica dos Santos [1 ]
Pepe, Vera Lucia Edais [2 ]
机构
[1] Fundacao Oswaldo Cruz, Programa Posgrad Saude Publ, Escola Nacl Saude Publ Sergio Arouca, R Leopoldo Bulhoes 1480, BR-21041210 Rio De Janeiro, RJ, Brazil
[2] Fundacao Oswaldo Cruz, Dept Adm & Planejamento Saude, Escola Nacl Saude Publ Sergio Arouca, Rio De Janeiro, RJ, Brazil
来源
CIENCIA & SAUDE COLETIVA | 2024年 / 29卷 / 07期
关键词
Emergencies; Health policy; Interna- tional cooperation; Health surveillance; Brazilian Health Surveillance Agency; MEDICINES; COVID-19; APPROVAL; AMERICA;
D O I
10.1590/1413-81232024297.03442024EN
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Public Health Emergencies (PHE) have had repercussions on health systems on a global scale, and timely access to new health technologies is a challenge for health policy. The national regulatory authorities (NRA) play a key role in the evaluation and regulation of these technologies. The present study aims to analyze the main strategies and regulatory instruments used to deal with the challenges of regulating new technologies necessary for the health system's effective response during a PHE. This research, based on WHO and Brazilian NRA norms and documents, considered dimensions related to strategies for strengthening regulatory activities and regulatory instruments used to accelerate access to technologies, especially during PHEs. International cooperation between the NRA and the WHO were important strategies for strengthening the NRA, with emphasis on the use of reliance, regionalization, accelerated assessments, and work/information sharing, as well as the processes of regulatory harmonization and convergence. In addition to the use of existing regulatory instruments, efforts were also identified in order to implement new ones.
引用
收藏
页数:13
相关论文
共 43 条
[11]  
Costa EA, 2013, Regulacao de medicamentos no Brasil, P21
[12]  
Cruz V., 2020, Rev Direito Sanitario, V10, P90
[13]  
Sandri MMD, 2013, REV PANAM SALUD PUBL, V34, P169
[14]   FDA Approval and Regulation of Pharmaceuticals, 1983-2018 [J].
Darrow, Jonathan J. ;
Avorn, Jerry ;
Kesselheim, Aaron S. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (02) :164-176
[15]   Reliance: a smarter way of regulating medical products-The IPRP survey [J].
Doerr, Petra ;
Valentin, Marie ;
Nakashima, Nobumasa ;
Orphanos, Nick ;
Santos, Gustavo ;
Balkamos, Georgios ;
Saint-Raymond, Agnes .
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (02) :173-177
[16]   Regulatory reliance to approve new medicinal products in Latin American and Caribbean countries [J].
Duran, Carlos E. ;
Canas, Martin ;
Urtasun, Martin A. ;
Elseviers, Monique ;
Andia, Tatiana ;
Vander Stichele, Robert ;
Christiaens, Thierry .
REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH, 2021, 45
[17]   COVID-19 and the medicines regulation challenges in times of pandemic [J].
Edais Pepe, Vera Lucia ;
Dutilh Novaes, Hillegonda Maria ;
Serpa Osorio-de-Castro, Claudia Garcia .
CIENCIA & SAUDE COLETIVA, 2021, 26 (10) :4693-4702
[18]  
Flexa RGC, 2019, Vigil Sanit Debate, V7, P3
[19]   Pharmaceutical Strategy for Europe: Reflections on Public Health-Driven Drug Development, Regulation, and Policies [J].
Garattini, Silvio ;
Natsis, Yannis ;
Banzi, Rita .
FRONTIERS IN PHARMACOLOGY, 2021, 12
[20]   The European Medicines Agency is still too close to industry [J].
Garattini, Silvio .
BMJ-BRITISH MEDICAL JOURNAL, 2016, 353